Dr Mike Evans is a long-time senior executive and board member in the life sciences industry with a successful track record of transforming businesses and leading them to successful exits.

Mike was formerly CEO of Oxford Gene Technology (“OGT”) for 13 years, where he led the company’s transformation from a licensing-led business model to a highly successful genomic products business before its sale to Sysmex Corporation in 2017. Before joining OGT, Mike held a number of senior positions at GE Healthcare/Amersham Biosciences, including Executive Vice President, Marketing and Strategy and Executive Vice President, Corporate Development. Mike previously served as Managing Director, Fine Chemicals at Ascot plc. Mike has also held several non-executive directorships and was Chairman of TAP Biosystems Group plc until its sale to Sartorius Stedim Biotech.

Mike is currently an Executive Advisor  at Ampersand Capital and is non-executive director at Tjoapack.